



Great debates in Hematology

Saturday, 8th June 2024, 9.00 am - 5.00 pm

Venue: Conference Hall, P D Hinduja Hospital, Mahim, Mumbai

Each debate will be for 25 minutes (10 minutes each for the speaker and 5 minutes for rebuttal and discussion)

Time	Subject	Speaker
9.00 am - 9.30 am	Fellowship (Breakfast)	
9.30 am - 9.50 am	Quiz for UG, PG & DM students	Quiz Master Dr. M. B. Agarwal
9.50 am - 10.00 am	Welcome address	Dr. Shanaz Khodaiji
Debate 1		
10.00 am - 10.30 am	Chair: Dr. Varsha Vadera, Dr. V. P. Antia, Dr. Girish Rajadhyaksha Iron therapy should preferably be oral. vs Iron therapy should preferably be parenteral.	Dr. Ruchira Misra vs Dr. Swati Kanakia
Debate 2		
10.30 am - 11.00 am	Chair: Dr. Shubhangi Agale, Dr. Vrinda Kulkarni, Dr. Sujata Sharma Splenectomy is obsolete in the treatment of ITP. vs Splenectomy remains an effective modality of treatment of ITP.	Dr. Asha Shah vs Dr. Farah Jijina
Debate 3		
11.00 am - 11.30 am	Chair: Dr. Samir Shah, Dr. Anjana Sainani, Dr. Prathamesh Kulkarni In the treatment of DLBCL, Polatuzumab Vedotin based treatment is a dramatic shift. vs In the treatment of DLBCL, Polatuzumab Vedotin based treatment is just a small step forward.	Dr. Subhaprakash Sanyal vs Dr. Aditi Shah Kaskar
Debate 4		
11.30 am - 12.00 pm	Chair: Dr. Ambreen Pandrowala, Dr. Bipin Kulkarni, Dr. Rucha Patil Non-factor based therapy makes factor based replacement therapy obsolete in the care of hemophilia. vs Even in the era of non-factor based therapy, factor replacement based therapy remains the standard of care for hemophiliacs.	Dr. Chandrakala S vs Dr. Ritika Khurana
Debate 5		
12.00 pm - 12.30 pm	Chair: Dr. Amar Dasgupta, Dr. Namita Padwal, Dr. Govind Kendre, Dr. Omkar Khandkar DOACs replace warfarin as the oral anticoagulant of choice. vs Warfarin, the old horse, still remains the oral anticoagulant of choice.	Dr. Rajesh Patil vs Dr. Shilpa Gupta
Debate 6		
12.30 pm - 1.00 pm	Chair: Dr. Manisha Madkaikar, Dr. Shweta Bansal, Dr. Adwaita Gore, Dr. Kriti Hegde ATG + Cyclosporin + Eltrombopag is the standard of care for most acquired aplastic anemia. vs Stem cell therapy is the standard of care for most acquired aplastic anemia.	Dr. Shrinath Kshirsagar vs Dr. Priti Mehta

Time	Subject	Speaker
1.00 pm - 1.45 pm	Lunch	
Debate 7		
1.45 pm - 2.15 pm	<p>Chair: Dr. Rohit Pai, Dr. Bharat Bhosale</p> <p>Brentuximab Vedotin (BV) based treatment is the best for Relapsed/Refractory Hodgkin Lymphoma</p> <p>vs</p> <p>Checkpoint inhibitors (Nivo / Pembro) based therapy replaces BV in the treatment of R/R HL</p>	<p>Dr. Subhaprakash Sanyal</p> <p>vs</p> <p>Dr. Rajesh Patil</p>
Debate 8		
2.15 pm - 2.45 pm	<p>Chair:</p> <p>Dr. Kunal Sehgal, Dr. Syed Hasan, Dr. Vipin Khandelwal</p> <p>Even a young-fit AML should receive HMA + Ven as a bridge to transplant.</p> <p>vs</p> <p>7+3 or similar chemo based protocol is necessary for young-fit AML patients needing transplant.</p>	<p>Dr. Punit Jain</p> <p>vs</p> <p>Dr. Sumeet Mirgh</p>
Debate 9		
2.45 pm - 3.15 pm	<p>Chair:</p> <p>Dr. Ganapathi Bhatt, Dr. Ashish Joshi, Dr. Chetan Dhamne, Dr Amrit Kaur Kaler</p> <p>For relapsed adult B-cell ALL, Inotuzumab Vedotin monotherapy is the best bridge to transplant.</p> <p>vs</p> <p>For relapsed adult B-cell ALL, Hyper-C-VAD with or without Blinatumomab is the best bridge to transplant.</p>	<p>Dr. Hamza Dalal</p> <p>vs</p> <p>Dr. Lingaraj Nayak</p>
Debate 10		
3.15 pm - 3.45 pm	<p>Chair:</p> <p>Dr. Anand Deshpande, Dr. Mukesh Sanklecha, Dr. Chintan Vyas, Dr. Amit Jain</p> <p>Most sickle cell disease patients deserve a cure by transplant</p> <p>vs</p> <p>Transplant should be sparingly used for patients of sickle cell disease.</p>	<p>Dr. Santanu Sen</p> <p>vs</p> <p>Dr. Purva Kanvinde</p>
Debate 11		
3.45 pm - 4.15 pm	<p>Chair:</p> <p>Dr. Reetu Jain, Dr. Darshana Rane, Dr. Rizwan Shaikh, Dr. Anbarasan Sekar</p> <p>Daratumumab is necessary for all newly diagnosed myeloma patients.</p> <p>vs</p> <p>VRd without Daratumumab is adequate for most newly diagnosed myeloma patients:</p>	<p>Dr. Arun VA</p> <p>vs</p> <p>Dr. Bhausahab Bagal</p>
Debate 12		
4.15 pm - 4.45 pm	<p>Chair:</p> <p>Dr. Bhavna Parikh, Dr. Pratibha Amare Kadam, Dr. Akshay Shah, Dr. Parth Ganatra</p> <p>With the option of CAR-T for relapsed myeloma, autologous stem cell transplant is not needed for treatment of newly diagnosed myeloma.</p> <p>vs</p> <p>Autologous stem cell transplant still remains the standard of care for newly diagnosed myeloma, even with the option of CAR-T for the relapsed situation.</p>	<p>Dr. Gaurav Narula</p> <p>vs</p> <p>Dr. Reetu Jain</p>
Debate 13		
4.45 pm - 5.15 pm	<p>Chair:</p> <p>Dr. Gaurav Narula, Dr. Syed Hasan, Dr. Darshana Rane</p> <p>Ruxolitinib is a game changer for patients of MPN</p> <p>vs</p> <p>Ruxolitinib has added very little to the life of patients with MPN</p>	<p>Dr. Dipanjan Haldar</p> <p>vs</p> <p>Dr. Hamza Dalal</p>
5.15 pm - 5.30 pm	Prize distribution & concluding remarks	Dr. Vidisha Mahajan